Efficacy and safety of en bloc transurethral resection of bladder tumor by 1 470 nm laser combined with immediate infusion of gemcitabine in the treatment of non-muscular-invasive bladder cancer
SHI Bing1, MA Yinfeng2, WANG Wei1
1Department of Urology, Nantong Hospital of Traditional Chinese Medicine, Nantong 226001, China; 2Department of Urology, the Second Clinical Medical College of Zhejiang Chinese Medicine University
Abstract：Objective: To investigate the clinical effect of 1470 nm laser in the treatment of non-muscular-invasive bladder cancer （NMIBC）. Methods: From August 2016 to February 2018, 42 cases of NMIBC were treated with 1 470 nm laser transurethral resection of bladder tumor and immediate infusion of gemcitabine in The Second Clinical Medical College of Zhejiang Chinese Medicine University. The operation time, intraoperative hemorrhage, intraoperative complications, indwelling days of catheter, length of hospital stay and postoperative disease stage were analyzed. The recurrence and progress of the patients were followed up, and the recurrent rate was statistically analyzed according to the pathological classification and stage stratification. Results: Totally 42 cases were operated smoothly. The operation time was 18.0-45.0 min （mean 32.4 ± 7.8）. No obvious bleeding, obturator nerve reflex and bladder perforation occurred. Postoperative indwelling catheterization ranged from 3.0 to 5.0 days （mean 4.2 ± 0.8 days）, hospital stay ranged from 4.0 to 8.0 days （mean 6.5 ± 0.7 days）. There were 8 cases of low-grade urothelial papilloma, 20 cases of low-grade urothelial carcinoma, 14 cases of high-grade urothelial carcinoma, 11 cases of Ta stage, 31 cases of T1 stage. After 18 months of follow-up. Totally 5 patients had recurrence （11.9%）. The recurrence rate in TA phase and T1 phase was 9.0% （1/11） and 12.9% （4/31） respectively. Conclusion: It is safe and effective to treat NMIBC with en bloc transurethral resection of bladder tumor by 1 470 nm laser combined with immediate infusion of gemcitabine.
石兵, 马寅锋, 王伟. 1 470 nm激光经尿道膀胱肿瘤整块切除联合吉西他滨即刻灌注治疗非肌层浸润性膀胱癌的疗效及安全性分析[J]. 微创泌尿外科杂志, 2021, 10(1): 27-30.
SHI Bing, MA Yinfeng, WANG Wei. Efficacy and safety of en bloc transurethral resection of bladder tumor by 1 470 nm laser combined with immediate infusion of gemcitabine in the treatment of non-muscular-invasive bladder cancer. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2021, 10(1): 27-30.
[1] 那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014版).北京:人民卫生出版社,2014:20-42. [2] 王国民,陈伟.泌尿系统肿瘤治疗的进展与展望.肿瘤防治研究,2014,41(2):97-101. [3] BISHR M, LATTOUF JB, LATOUR M, et al.Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J, 2014,8(5/6):E306-E310. [4] 杨玉帛,刘振华,韩平.经尿道膀胱肿瘤整块切除术的研究进展.临床泌尿外科杂志,2017,32(10):775-778. [5] 陈令秋,乙从亮,杨登伦,等.TURBT对非肌层浸润性膀胱癌复发的影响.实用癌症杂志,2015,30(5):783-785. [6] ENGILBERTSSON H, AALTONEN KE, BJORNSSON S, et al.Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol, 2015,193(1):53-57. [7] WILBY D, THOMAS K, RAY E, et al.Bladder cancer: new TUR techniques. World J Urol, 2009,27(3):309-312. [8] WEZEL F, WENDT-NORDAHL G, HUCK N, et al.New alternatives for laser vaporization of the prostate: experimental evaluation of a 980-,1 318- and 1 470-nm diode laser device. World J Urol, 2010,28(2):181-186. [9] 周发友,章小毅,王允武,等.经尿道1470纳米半导体激光汽化术治疗前列腺增生的疗效分析.中国内镜杂志,2016,22(12):26-29. [10] 周发友,张书贤,王允武,等.1470nm激光悬挑法剜除术治疗非肌层浸润性膀胱肿瘤.中华腔镜泌尿外科杂志(电子版),2019,13(1):52-55. [11] WU YP, LIN TT, CHEN SH, et al.Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: A meta-analysis. Medicine, 2016,95(45):e5372. [12] 易文发,曹会彦,刘智明,等.经尿道1470nm半导体激光与TURBT治疗表浅性膀胱肿瘤的临床疗效比较.临床泌尿外科杂志,2015,30(12):1132-1134. [13] 任晓磊,郭俊生,崔向宇,等.1470nm激光经尿道汽化切除高龄高危浅表性膀胱癌的疗效观察.中华腔镜泌尿外科杂志(电子版),2017,11(6):416-418. [14] 常德辉,张伟君,吕海迪,等.经尿道1470nm激光整块剜除膀胱肿瘤的临床疗效分析及其对精确病理分期的影响.现代泌尿外科杂志,2018,23(7):504-507. [15] HENDRICKSEN K, WITJES WP, IDEMA JG, et al.Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol, 2008,53(5):984-991. [16] BERRUM-SVENNUNG I, GRANFORS T, JAHNSON S, et al. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol, 2008,179(1):101-105; discussion 105-106. [17] 刘秋莲. 吉西他滨对膀胱癌细胞敏感性的实验分析.中国医药指南,2012,(29):441-442. [18] 邓湘宁,张远卓.肿瘤药物对人膀胱癌细胞生长抑制效果的研究.中国现代医学杂志,2014,24(15):35-38.
